{"ModuleTitle": "Company Description", "CompanyName": "Pacira BioSciences, Inc.", "Symbol": "PCRX", "Address": "5 SYLVAN WAY SUITE 300, PARSIPPANY, New Jersey, 07054, United States of America", "Phone": "973-254-3560", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "Pacira BioSciences, Inc., a Delaware corporation, changed its name from Pacira\r\nPharmaceuticals, Inc. upon completing its acquisition of MyoScience, a\r\nprivately-held medical technology company, in April 2019 (referred to herein as\r\nthe \"MyoScience Acquisition\") in order to better reflect a broadening portfolio\r\nof innovative non-opioid pain management and regenerative health solutions.\r\nPacira BioSciences, Inc. is the holding company for our California operating\r\nsubsidiary named Pacira Pharmaceuticals, Inc., or Pacira California. In March\r\n2007, we acquired Pacira California from SkyePharma Holdings, Inc. (now a\r\nsubsidiary of Vectura Group plc), or Skyepharma (referred to herein as the\r\n\"Skyepharma Acquisition\"). Pacira California retained the name Pacira\r\nPharmaceuticals, Inc. upon the completion of the MyoScience Acquisition. Unless\r\nthe context requires otherwise, references to \"Pacira,\" \"we,\" the \"Company,\"\r\n\"us\" and \"our\" in this Annual Report refers to Pacira BioSciences, Inc.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f21%2f0001396814-20-000008.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Charles A. Reinhart", "title": "Chief Financial Officer"}, {"name": "Charles Anthony Laranjeira", "title": "Chief Technology Officer"}, {"name": "David M. Stack", "title": "Chairman, Chief Executive & Operating Officer"}, {"name": "Donald C. Manning", "title": "Chief Medical Officer"}, {"name": "Vladimir Kharitonov", "title": "Vice President-Research & Development"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}